Abiraterone Acetate Tablets

Abiraterone Acetate is classed as a CYP17 inhibitor (antiandrogen antineoplastic) and is supplied as tablets. Its standard indications include metastatic prostate cancer, and it is offered for pharmaceutical supply and export.

Specifications are indicative; availability, composition, pack sizes and registration requirements may vary by destination market.